<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336560">
  <stage>Registered</stage>
  <submitdate>18/02/2011</submitdate>
  <approvaldate>4/03/2011</approvaldate>
  <actrnumber>ACTRN12611000241932</actrnumber>
  <trial_identification>
    <studytitle>CoQ10 treatment in inadequately treated hypertensive patients with the metabolic syndrome.</studytitle>
    <scientifictitle>A double-blind, randomised, placebo controlled, 12-week cross-over study to assess the effect of Coenzyme Q10 treatment on 24hr mean ambulatory systolic and diastolic blood pressure in inadequately treated hypertensive patients with the metabolic syndrome.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <healthcondition>The Metabolic Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Coenzyme Q10 (100mg twice daily) or placebo (twice daily) for 12 weeks via oral capsule, followed by a 4-week washout period, then 12 weeks of the alternate 'treatment'.</interventions>
    <comparator>Placebo - oral capsule identical in appearance to the active treatment.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether 24-hour mean ambulatory systolic and diastolic blood pressure is lowered by 12 weeks of CoQ10 therapy in patients with the metabolic syndrome who have inadequately treated hypertension. Twenty-four hour ambulatory BP monitoring will be assessed using the oscillometric technique with a non-invasive monitor and self-inflating cuff.</outcome>
      <timepoint>After 12 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether CoQ10 lowers resting mean clinic systolic and mean clinic diastolic blood pressure. Clinic blood pressure was measured using standard sphygmomanometry.</outcome>
      <timepoint>After 12 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Hypertension (average sitting systolic BP of &gt;139 mmHg or &gt;129/80 if patient has type II diabetes) and stabilised on antihypertensives for at least 1 month.
The metabolic syndrome</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Uncontrolled hypertension
Cerebrovascular accident within 12 months prior
Taking warfarin treatment or antioxidant vitamin supplements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A screening visit will assess eligibility, and after the two week screening visit, eligible patients will be randomised to treatment with either CoQ10 or placebo. Patients and investigators will be blinded to treatments.</concealment>
    <sequence>Randomisation will be performed in permutation blocks from a computer generated randomisation list. The study treatments will be dispensed by an independent pharmacist in identical numbered bottles with the lowest available number allocated to each sequential participant.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>Placebo controlled</designfeatures>
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/12/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Canterbury Health Laboratories</primarysponsorname>
    <primarysponsoraddress>P.O. Box 151
Christchurch, 8140</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation of New Zealand</fundingname>
      <fundingaddress>9 Kalmia Street, Ellerslie
P.O. Box 17160, Greenlane
Auckland 1546</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Canterbury District Health Board</sponsorname>
      <sponsoraddress>P.O. Box 151
Christchurch, 8140</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>CoQ10 has been reported to lower blood pressure. We are giving supplemental CoQ10 to 30 participants with the metabolic syndrome and uncontrolled high blood pressure, despite medication, to determine whether CoQ10 can further lower their blood pressure, and reduce their risk of serious disease.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Upper South B Regional Ethics Committee (New Zealand)</ethicname>
      <ethicaddress>Ministry of Health
4th Floor, 250 Oxford Tce
PO Box 3877
Christchurch, 8140</ethicaddress>
      <ethicapprovaldate>21/10/2008</ethicapprovaldate>
      <hrec>URB/08/09/041</hrec>
      <ethicsubmitdate>6/09/2008</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sarah Molyneux</name>
      <address>Canterbury Health Laboratories
Biochemistry Unit
P.O. Box 151
Christchurch, 8140</address>
      <phone>+64 3 3641594</phone>
      <fax />
      <email>sarah.molyneux@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Molyneux</name>
      <address>Canterbury Health Laboratories
Biochemistry Unit
P.O. Box 151
Christchurch, 8140</address>
      <phone>+64 3 3641594</phone>
      <fax />
      <email>sarah.molyneux@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Molyneux</name>
      <address>Canterbury Health Laboratories
Biochemistry Unit
P.O. Box 151
Christchurch, 8140</address>
      <phone>+64 3 3641594</phone>
      <fax />
      <email>sarah.molyneux@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>